Pages that link to "Q43274091"

The following pages link to Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms (Q43274091):

Displaying 14 items.

• Pharmacogenetic studies update in type 2 diabetes mellitus (Q26739350) (← links)
• KCNJ11: Genetic Polymorphisms and Risk of Diabetes Mellitus (Q28085471) (← links)
• Personalized medicine in Type 2 Diabetes (Q28542708) (← links)
• KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment. (Q33771570) (← links)
• Identification of genetic variants in pharmacogenetic genes associated with type 2 diabetes in a Mexican-Mestizo population (Q33858377) (← links)
• Pharmacogenetics and personalized treatment of type 2 diabetes (Q37508445) (← links)
• Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation (Q38711541) (← links)
• The Application of Genomics in Diabetes: Barriers to Discovery and Implementation (Q39123582) (← links)
• Association between E23K variant in KCNJ11 gene and new-onset diabetes after liver transplantation (Q42208034) (← links)
• KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients (Q51317485) (← links)
• Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine (Q90267161) (← links)
• Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care (Q96172065) (← links)
• Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes (Q99545741) (← links)
• Pharmacogenetics of Type 2 Diabetes-Progress and Prospects (Q99605020) (← links)